Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1 million. Black Diamond, which founding investor Versant Ventures launched in 2014 to develop tumor-agnostic small molecule therapies, had

Read the full 521 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers